FY2030 Earnings Estimate for Alector Issued By HC Wainwright

Alector, Inc. (NASDAQ:ALEC) – HC Wainwright issued their FY2030 earnings per share estimates for Alector in a research note issued on Friday, February 27th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.58) for the year. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share.

Alector (NASDAQ:ALEC) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.05. Alector had a negative net margin of 679.16% and a negative return on equity of 224.96%. The company had revenue of $6.24 million for the quarter, compared to analysts’ expectations of $1.78 million.

ALEC has been the topic of several other reports. Morgan Stanley reaffirmed an “underweight” rating on shares of Alector in a research note on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Alector from a “hold” rating to a “sell” rating in a research report on Sunday. Finally, BTIG Research raised shares of Alector from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alector presently has a consensus rating of “Hold” and an average price target of $3.25.

Alector Stock Down 5.1%

ALEC stock opened at $2.43 on Monday. Alector has a fifty-two week low of $0.87 and a fifty-two week high of $3.40. The company has a market capitalization of $268.17 million, a price-to-earnings ratio of -1.75 and a beta of 0.57. The business’s 50 day moving average price is $1.85 and its two-hundred day moving average price is $2.03. The company has a debt-to-equity ratio of 0.30, a quick ratio of 3.83 and a current ratio of 3.83.

Institutional Investors Weigh In On Alector

Several large investors have recently bought and sold shares of the business. Foresite Capital Management IV LLC bought a new position in Alector during the 4th quarter valued at about $6,064,000. Balyasny Asset Management L.P. bought a new position in shares of Alector during the 4th quarter valued at $5,094,000. 683 Capital Management LLC boosted its stake in shares of Alector by 235.0% in the 4th quarter. 683 Capital Management LLC now owns 3,350,000 shares of the company’s stock worth $5,226,000 after buying an additional 2,350,000 shares during the last quarter. Ikarian Capital LLC boosted its stake in shares of Alector by 174.0% in the 4th quarter. Ikarian Capital LLC now owns 2,082,606 shares of the company’s stock worth $3,249,000 after buying an additional 1,322,606 shares during the last quarter. Finally, Spruce Street Capital LP bought a new stake in shares of Alector in the fourth quarter worth $1,744,000. 85.83% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Alector news, CFO Neil Lindsay Berkley sold 37,261 shares of Alector stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $1.12, for a total value of $41,732.32. Following the completion of the sale, the chief financial officer owned 374,309 shares of the company’s stock, valued at approximately $419,226.08. This trade represents a 9.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Arnon Rosenthal sold 104,347 shares of the business’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $1.12, for a total value of $116,868.64. Following the completion of the transaction, the chief executive officer owned 2,420,040 shares of the company’s stock, valued at $2,710,444.80. This represents a 4.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 200,183 shares of company stock worth $230,262 in the last three months. Insiders own 9.70% of the company’s stock.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.